# Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant

> **NCT02118896** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Europe Ltd.** · enrollment: 850 (actual)

## Conditions studied

- Heart Transplantation
- Liver Transplantation
- Kidney Transplantation

## Interventions

- **DRUG:** FK506E

## Key facts

- **NCT ID:** NCT02118896
- **Lead sponsor:** Astellas Pharma Europe Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02-24
- **Primary completion:** 2009-10-07
- **Final completion:** 2009-10-07
- **Target enrollment:** 850 (ACTUAL)
- **Last updated:** 2024-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02118896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02118896, "Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02118896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*